1-20 of 35
Iris Isufi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Ramzi Hamouche, Francine M. Foss, Sayeef Mirza, Mengyang Di, Iris Isufi, Noffar Bar, Lohith Gowda, Sarah Perreault, Kenneth Roberts, Stuart Seropian, Tarsheen Sethi
Journal: Blood
Blood (2023) 142 (Supplement 1): 2172.
https://doi.org/10.1182/blood-2023-189414
Published: 2023
Journal Articles

Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype

Anuj Verma, Samuel Liburd, Zsuzsanna Tobias, Iris Isufi, Jordan Pober, Mina L Xu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2075.
https://doi.org/10.1182/blood-2023-184963
Published: 2023
Journal Articles

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Tariq Kewan, Sayeef Mirza, Alexander B Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean X Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian
Journal: Blood
Blood (2023) 142 (Supplement 1): 2132.
https://doi.org/10.1182/blood-2023-187295
Published: 2023
Journal Articles

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C Minnema, Leyla Shune, Iris Isufi, Simon J. Harrison, Urvi A Shah, Jordan M. Schecter, Nikoletta Lendvai, Katharine S Gries, Eva G Katz, Ana Slaughter, Carolina Lonardi, Jane Gilbert, Quanlin Li, William Deraedt, Octavio Costa Filho, Nitin Patel, Lionel Karlin, Katja Weisel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1063.
https://doi.org/10.1182/blood-2023-178798
Published: 2023
Journal Articles

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Steven M. Bair, Mayur Narkhede, Zachary AK Frosch, Elise A. Chong, Daniel A. Ermann, Iris Isufi, Farrukh T. Awan, Julio C Chavez, Grace N Bosma, Diana Abbott
Journal: Blood
Blood (2023) 142 (Supplement 1): 68.
https://doi.org/10.1182/blood-2023-187113
Published: 2023
Journal Articles

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Christian Grommes, Han Tun, Allison C. Rosenthal, Matthew A Lunning, Radhakrishnan Ramchandren, Lucia Regales, Wanying Zhao, Maureen Lane, Catherine Wang, Reinhard von Roemeling, Iris Isufi, Lori A. Leslie, Grzegorz S. Nowakowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4497.
https://doi.org/10.1182/blood-2023-189746
Published: 2023
Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Sanjal H. Desai, Nuttavut Sumransub, Rich Evans, Marcus P Watkins, Reem Karmali, Gaurav Goyal, Mitchell E. Hughes, Arushi Khurana, Francisco J. Hernandez-Ilizaliturri, Joanna Zurko, Ayesha Hassan, Haris Hatic, Imran A. Nizamuddin, Andrew M Evens, Andrea Carolina Anampa-Guzmán, Yi Lin, Iris Isufi, Mehdi Hamadani, Saurabh A Rajguru, Naveena Lall, Aung M. Tun, Brian T. Hill, Deborah M. Stephens, Paolo F. Caimi, Daniel A. Ermann, Brad S. Kahl, Daniel J. Landsburg, Grzegorz S. Nowakowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 308.
https://doi.org/10.1182/blood-2023-183001
Published: 2023
Journal Articles

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Jennifer L. Crombie, Loretta J. Nastoupil, Charalambos Andreadis, Iris Isufi, Bradley Hunter, Allison Winter, Brian Hess, Stefan K. Barta, Michael J. Frigault, Maria Lia Palomba, Natalie S. Grover, Michael D. Jain, Tamara K. Moyo, Sagar S. Patel, Priyanka A Pophali, David Bernasconi, Charimar Santiago Parrilla, Amani Kitali, Fei Fei Liu, Mecide Gharibo, Marcelo Pasquini
Journal: Blood
Blood (2023) 142 (Supplement 1): 104.
https://doi.org/10.1182/blood-2023-180242
Published: 2023
Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Reid W Merryman, Robert A. Redd, Arnold S. Freedman, Inhye E. Ahn, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric D Jacobsen, Austin I. Kim, Ann S. LaCasce, Samuel Ng, Oreofe O. Odejide, Erin Michelle Parry, Iris Isufi, Justin Kline, Jonathon B. Cohen, Neha Mehta-Shah, Nancy L. Bartlett, Matthew Mei, Philippe Armand, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 6531–6533.
https://doi.org/10.1182/blood-2022-159823
Published: 2022
Journal Articles

Improving Diversity, Equity, and Inclusion Education in Hematology/Oncology Training

Anna Kress, Benjamin Lu, Ayesha Butt, Jana Christian, Nikolai A. Podoltsev, Michael Hurwitz, Sarah Goldberg, Barbara Burtness, Iris Isufi, Darin Latimore, Alfred I. Lee, Pamela Kunz
Journal: Blood
Blood (2022) 140 (Supplement 1): 5029–5030.
https://doi.org/10.1182/blood-2022-170950
Published: 2022
Journal Articles

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Hun Ju Lee, Michael Y. Choi, Tanya Siddiqi, Joanna M. Rhodes, William G. Wierda, Iris Isufi, Joseph M Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Michael Wang, Catriona Jamieson, Thomas J. Kipps
Journal: Blood
Blood (2022) 140 (Supplement 1): 566–568.
https://doi.org/10.1182/blood-2022-167153
Published: 2022
Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian
Journal: Blood
Blood (2022) 140 (Supplement 1): 10410–10412.
https://doi.org/10.1182/blood-2022-168374
Published: 2022
Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 774–776.
https://doi.org/10.1182/blood-2022-167626
Published: 2022
Journal Articles

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Madiha Iqbal, Arushi Khurana, Julio Chavez, Allison C. Rosenthal, Zhuo Li, Emily Craver, Saha Aditi, Narendranath Epperla, Kaitlin Annunzio, Farrukh T. Awan, Iris Isufi, Bhagirathbhai Dholaria, Shakthi Bhaskar, Joseph Maakaron, Nuttavut Sumransub, Andrew Fijalka, Jose Sandoval-Sus, Stanislav Ivanov, Yi Lin, Mohamed A. Kharfan-Dabaja
Journal: Blood
Blood (2022) 140 (Supplement 1): 10396–10398.
https://doi.org/10.1182/blood-2022-169689
Published: 2022
Journal Articles

Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Sanjal H Desai, Marcus P. Watkins, Reem Karmali, Gaurav Goyal, Mitchell Hughes, Arushi Khurana, Francisco Hernandez-Ilizaliturri, Nuttavut Sumransub, Joanna Zurko, Imran A. Nizamuddin, Haris Hatic, Daniel A Landsburg, Andrea Anampa-Guzman, Mehdi Hamadani, Yi Lin, Iris Isufi, Aung M Tun, Brian T. Hill, Deborah M. Stephens, Paolo F Caimi, Daniel A. Ermann, Brad S. Kahl, Grzegorz S. Nowakowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 10391–10393.
https://doi.org/10.1182/blood-2022-159725
Published: 2022
Journal Articles

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Mengyang Di, Jessica B Long, Iris Isufi, Francine M. Foss, Stuart Seropian, Cary P Gross, Scott F. Huntington
Journal: Blood
Blood (2022) 140 (Supplement 1): 10818–10819.
https://doi.org/10.1182/blood-2022-164915
Published: 2022
Journal Articles

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Hun Ju Lee, Michael Choi, Tanya Siddiqi, Jacqueline Barrientos, William G. Wierda, Iris Isufi, Joseph Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori A. Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Yao Wang, Michael Wang, Catriona Jamieson, Thomas J. Kipps
Journal: Blood
Blood (2021) 138 (Supplement 1): 3534.
https://doi.org/10.1182/blood-2021-148779
Published: 2021
Journal Articles

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Anthony R. Mato, MD, Stephen J. Schuster, MD, Francine M. Foss, MD, Iris Isufi, MD, Shalin K. Kothari, MD, Wei Ding, MD PhD, Danielle M. Brander, MD, Andrea Sitlinger, MD, Allison C. Rosenthal, D.O., Jose F. Leis, MD PhD, Han W. Tun, MD, Kaitlin Kennard, RN, BSN, Allison R. Nelson, RN, Victoria Falco, BSN, Celina J. Komari, BS, Amber B. Koehler, PA-C, MS, Rachel Stowe, RN, Wei He, PhD, Albert Kearney, PhD, Min Gui, PhD, Tim McKinlay, Lindsey E Roeker, MD, Meghan C. Thompson, MD, Scott F. Huntington, MD MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-138896
Published: 2020
Journal Articles

Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Megan Lee, BS, Molly Schiffer, PharmD, Iris Isufi, MD, Scott F. Huntington, MD MPH, Mina L. Xu, MD, Stuart Seropian, MD, Lohith Gowda, MD, Shalin K. Kothari, MD, Michael Girardi, MD PhD, Francine M. Foss, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-139790
Published: 2020
Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Hun Ju Lee, MD, Michael Y. Choi, MD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Jacqueline C. Barrientos, MD, Nicole Lamanna, MD, Alec Goldenberg, MD, Iris Isufi, MD, Joseph Tuscano, MD, Suki Subbiah, MD, Jean L. Koff, MD, Lori A. Leslie, MD, Gina G Chung, MD, Elizabeth K Weihe, MD, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Frank J Hsu, MD, Michael Wang, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141917
Published: 2020